首页> 外文期刊>The EPMA journal. >Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer
【24h】

Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer

机译:解锁潘多拉魔盒:个性化非小细胞肺癌中的癌细胞死亡

获取原文
           

摘要

Evasion of apoptosis is a hallmark of tumorigenesis and a recognised cause of multidrug resistance. Over the last decade, insights into how apoptosis might be exploited in non-small cell lung cancer ( NSCLC ) and how cancer therapeutics might be used to engage apoptotic signalling in a personalised manner have changed markedly. We are now in the wake of a paradigm shift in stratified therapeutic approaches related to NSCLC . At the heart of this shift in thinking is the emerging knowledge that even the most drug-resistant cancers exhibit a functional death pathway and, critically, that this pathway can be efficiently engaged, leading to clinical benefit. This review will summarise current knowledge of mitochondrial apoptotic pathway dysfunction in NSCLC and how the next generation of targeted therapeutics might be used to exploit deficiencies in apoptotic signalling in a personalised manner to improve clinical outcome and predict therapeutic benefit.
机译:规避细胞凋亡是肿瘤发生的标志,也是公认的多药耐药性原因。在过去的十年中,关于如何在非小细胞肺癌(NSCLC)中利用凋亡以及如何利用癌症治疗剂以个性化方式参与凋亡信号的见解发生了显着变化。我们现在正与NSCLC有关的分层治疗方法发生范式转变。这种思想转变的核心是不断出现的知识,即即使是大多数耐药性癌症也都具有功能性死亡途径,并且至关重要的是,这种途径可以有效参与,从而带来临床益处。这篇综述将总结NSCLC中线粒体凋亡途径功能障碍的当前知识,以及如何以个性化方式利用下一代靶向疗法来利用凋亡信号的不足来改善临床结果并预测治疗获益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号